🇺🇸 Kalcipos-D in United States

399 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 56 reports (14.04%)
  2. Nausea — 55 reports (13.78%)
  3. Pyrexia — 43 reports (10.78%)
  4. Dyspnoea — 42 reports (10.53%)
  5. Headache — 42 reports (10.53%)
  6. Diarrhoea — 39 reports (9.77%)
  7. Dizziness — 36 reports (9.02%)
  8. Pain In Extremity — 30 reports (7.52%)
  9. Atrial Fibrillation — 28 reports (7.02%)
  10. Drug Interaction — 28 reports (7.02%)

Source database →

Frequently asked questions

Is Kalcipos-D approved in United States?

Kalcipos-D does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Kalcipos-D in United States?

Takeda is the originator. The local marketing authorisation holder may differ — check the official source linked above.